Lilly aims for Japan top 10 on new launches
This article was originally published in Scrip
Lilly remains bullish about its business in Japan on the back of strong sales increases over the past few years, and is confident it can achieve a top 10 ranking in the industry by 2020 following a slew of launches this year.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.